WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients

University Hospital, Clermont-Ferrand20 enrolled

Overview

The SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of sedation often reveals a pathological awakening in the vast majority of patients. This encephalopathy state remains, to date and to our knowledge, unexplained. Clinical features do not appear to fully correlate with regular delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use of sedation drugs, systemic inflammation or the hostile ICU environment.

This study is intended to investigate neurological abnormalities associated with SARS-CoV-2 infection. Complete daily neurological examinations will be routinely conducted in intensive care unit patients. Specific biological analyses will also be performed in these patients by collecting additional blood samples from an arterial or central catheter, every 2 days. These clinical and biological examinations will be continued throughout patient's stay in the intensive care unit.

Study Type

OBSERVATIONAL

Enrollment

Conditions

SARS-CoV-2 Infection Intensive Care Unit Patient Neurological Abnormality Delirium Encephalopathy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years old * COVID-19 positive patient (positive RT PCR, nasopharyngeal or tracheal) * Patient admitted in an intensive care unit of the department of Anesthesia, Critical Care and Perioperative of Clermont-Ferrand University Hospital * Patient with an arterial or central catheter to perform blood samples collection Exclusion Criteria: * Patient or family member's refusal to participate * Neuropsychiatric history that may interfere with neurological evaluations in the intensive care unit * Patient not affiliated with French social security insurance * Patient under legal guardianship

Locations (1)

CHU

Clermont-Ferrand, France

RECRUITING

Outcomes

Primary Outcomes

Dosage of biomarkers typically explored in intensive care unit delirium

Plasminogen activator inhibitor-1 (PAI-1), E-selectin and angiopoietin-2

Time frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days

Dosage of neuronal injury markers

S100 β, Neuron Specific Enolase (NSE), GFAP, UCHL1, NFL

Time frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days